Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LDLRAD4 antisense RNA 1 (LDLRAD4-AS1) is a long noncoding RNA (lncRNA) transcribed antisense to the LDLRAD4 gene. It is primarily nuclear in colorectal cancer cells, where it is upregulated and associated with poor prognosis. LDLRAD4-AS1 promotes colorectal cancer progression and metastasis by downregulating the mRNA stability of the LDLRAD4 gene, which acts as a suppressor of cell migration and epithelial-mesenchymal transition (EMT). By promoting EMT through upregulation of the transcription factor Snail and decreasing E-cadherin, LDLRAD4-AS1 enhances the invasive and migratory properties of cancer cells. It has been suggested as both a potential biomarker and a therapeutic target in colorectal cancer[1][2]. Key Notes: - The query referred to "LDLRAD4 antisense RNA 3 (LDLRAD4-AS3)", but scientific literature only validates "LDLRAD4 antisense RNA 1 (LDLRAD4-AS1)" as a functionally characterized lncRNA at the LDLRAD4 locus[1][2]. - No reputable sources or databases provide functional or disease-association data for "LDLRAD4-AS3", suggesting either a misspelling or else the target is not yet established in biomedical literature. - Descriptions, aliases, and roles above refer to LDLRAD4-AS1, the actual known molecule; LDLRAD4-AS3 cannot be accurately annotated given current evidence. - If user intent was to refer to a different antisense RNA at the LDLRAD4 locus, clarification is needed, but there is no basis for LDLRAD4-AS3 in major sources as of 2025[1][2]. Summary: No information is available for "LDLRAD4 antisense RNA 3 (LDLRAD4-AS3)" as a functionally characterized target. "LDLRAD4-AS1" is the canonical, disease-relevant lncRNA antisense to LDLRAD4, and this entry is for LDLRAD4-AS1 due to the apparent error in the query[1][2].
Not targeted by approved drugs; if targeted, downregulation would inhibit function as an oncogenic lncRNA
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LDLRAD4 antisense RNA 1 (LDLRAD4-AS1).